An interventional study of blood sampling in Locally Advanced Head and Neck Carcinoma, sponsored by Centre Jean Perrin. Recruiting at 4 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Centre Jean Perrin · Not applicable, Interventional, and Screening
Among 31 studies in Neoplasm, Residual with a site in France — 13 open to participants now, 17 under way, 2 of them phase 3. Neoplasm, Residual · France.
Among the 31 studies in Neoplasm, Residual with a site in France, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 with no phase, reaches primary completion later than 11 of the 16 other live ones, and was the 28th registered.
293 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.
Browse Neoplasm, Residual studies →13 of the 31 studies in Neoplasm, Residual with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
University Hospital, Montpellier · Sites in France
University Hospital, Montpellier · Sites in France
University Hospital, Montpellier · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 92 Neoplasm, Residual studies recruiting now, 58 (63%) set no upper age limit and 23 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 3
First in 2010; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 59 is above the median of 50 across 198 interventional studies indexed under Neoplasm, Residual.
Median enrollment 108 across the 15 interventional studies, 127 across the 16 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 31 have an industry lead sponsor. The 10 most frequent:
Centre Jean Perrin is the lead sponsor of 55 studies on the registry; 8 are open to participants now.
Centre Jean Perrin has 1 study filed under Neoplasm, Residual — fewer than ten, so there is no comparison to draw.
5 of the studies in Neoplasm, Residual with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05203003Assistance Publique - Hôpitaux de ParisProspective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment. | 2027-04 |
| NCT06287814University Hospital, MontpellierFrench Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) | 2027-04-11 |
| NCT04707300Assistance Publique - Hôpitaux de ParisStudy Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) | 2027-06 |
| NCT03876769Novartis PharmaceuticalsStudy of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients | 2027-10-19 |
| NCT04521231AmgenA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | 2027-11-24 |
Among the 31 studies in Neoplasm, Residual with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.
The main question it aims to answer is :
- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).
Participants will :
Selection Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: blood sampling
The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy
cDNA detection and objective response 3 months after the end of chemoradiotherapy
The detection or non detection of cDNA after treatment will be compared with the objective response (complete response versus progression/stability/partial response)
Time frame: 3 months after chemoradiotherapy
cDNA detection and objective response one month after the end of chemoradiotherapy
The detection or non detection of cDNA after treatment will be compared with the objective response (complete response versus progression/stability/partial response)
Time frame: 1 month after the end of chemoradiotherapy
Overall survival
The overall survival is defined as the time between the date of inclusion and the date of death from any cause.
Time frame: At the end of the main study (27 months after the end of treatment)
Progression-free survival
The progression-free survival is defined as the time between the date of inclusion and the date of the first progression of the disease (clinical or radiological) or death from any cause.
Time frame: At the end of the main study (27 months after the end of treatment)
cDNA kinetic
cDNA detection at 1 and 3 months after the end of chemoradiotherapy
Time frame: 1- and 3-month after the end of chemoradiotherapy
Concordance of mutational profiles and HPV-HR genotypes between primary tumor, ctDNA at diagnosis and ctDNA
This will be evaluated according to the mutational profile determined by NGS at each timepoint
Time frame: 1- and 3-months after the end of chemoradiotherapy
Determining the most frequent mutations.
That will be evaluated by analysing the results of NGS (among the 194 genes in our panel)
Time frame: 3-months after the end of chemoradiotherapy
Plan to share: Yes — The datasets used and/or analysed in the current study are available from the corresponding author on reasonable request.
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: The IPD and supporting information will be available from the publication of the results of the study until the beginning of archiving period.
Access criteria: Other researchers will be able to access the IPD and supporting information. It will be necessary to submit a proposal describing the planned analyses and/or to sign a data sharing agreement.
Started Oct 2025 (actual). Primary completion is estimated for Apr 2029, 42 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Jean Perrin